Tom Vink

4.9k citations

34 papers · 3.8k · 2 hit papers · h-index 26

Impact in

Hematology top 0.5%
- Platelet Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Blood groups and transfusion
Radiology, Nuclear Medicine and Imaging top 0.5%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Radiology, Nuclear Medicine and Imaging 17
- Monoclonal and Polyclonal Antibodies Research 17
Hematology 16
- Platelet Disorders and Treatments 12
- Blood groups and transfusion 9

Co-authors: Paul W.H.I. Parren (16 shared papers)Jan G. J. van de Winkel (10 shared papers)Wim K. Bleeker (7 shared papers)Jerry W. Slootstra (2 shared papers)Janine Schuurman (5 shared papers)Thomas Valerius (3 shared papers)Matthias Peipp (3 shared papers)Tamara H. den Bleker (2 shared papers)
Journals: Blood (8 papers)The Journal of Immunology (6 papers)Thrombosis and Haemostasis (5 papers)mAbs (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: Netherlands Germany United States

In The Last Decade

Tom Vink

34 papers receiving 3.7k citations

Tom Vink's Hit Papers

align trajectories log scale

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors 2010 · 767 citations

Peers

Countries citing papers authored by Tom Vink

Since Specialization

Citations

This map shows the geographic impact of Tom Vink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Vink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Vink more than expected).

Fields of papers citing papers by Tom Vink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Vink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Vink. The network helps show where Tom Vink may publish in the future.

Co-authors

The 25 scholars most cited alongside Tom Vink, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tom Vink Line = papers co-authored together Tom Vink links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors The Journal of Immunology ·Michel de Weers, Yu‐Tzu Tai, Michael S. van der Veer, Joost M. Bakker, Tom Vink, Daniëlle C.H. Jacobs, Lukas A. Oomen, Matthias Peipp, Thomas Valerius, Jerry W. Slootstra, Tuna Mutis, Wim K. Bleeker, Kenneth C. Anderson, Henk M. Lokhorst, Jan G. J. van de Winkel, Paul W.H.I. Parren Hit paper breakdown →	2010	767
2	Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange Science ·Marijn van der Neut Kolfschoten, Janine Schuurman, Mario Losen, Wim K. Bleeker, Pilar Martínez‐Martínez, Ellen Vermeulen, Tamara H. den Bleker, Luus Wiegman, Tom Vink, Lucien A. Aarden, Marc H. De Baets, Jan G. J. van de Winkel, Rob C. Aalberse, Paul W.H.I. Parren Hit paper breakdown →	2007	754
3	The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 The Journal of Immunology ·Jessica L. Teeling, Wendy J.M. Mackus, Luus Wiegman, Jeroen H. N. van den Brakel, Stephen A. Beers, Ruth R. French, Tom van Meerten, Saskia B. Ebeling, Tom Vink, Jerry W. Slootstra, Paul W.H.I. Parren, Martin J. Glennie, Jan G. J. van de Winkel	2006	497
4	Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells Blood ·Matthias Peipp, Jeroen J. Lammerts van Bueren, Tanja Schneider‐Merck, Wim W. K. Bleeker, Michael Dechant, Thomas Beyer, Roland Repp, Patrick H.C. van Berkel, Tom Vink, Jan G. J. van de Winkel, Paul W.H.I. Parren, Thomas Valerius	2008	178
5	Crosstalk between Human IgG Isotypes and Murine Effector Cells The Journal of Immunology ·Marije B. Overdijk, Sandra Verploegen, Antonio Ortiz Buijsse, Tom Vink, Jeanette H.W. Leusen, Wim K. Bleeker, Paul W.H.I. Parren	2012	164
6	Association between an agouti-related protein gene polymorphism and anorexia nervosa Molecular Psychiatry ·Tom Vink, Anke Hinney, Annemarie Elburg, Stephanie H.M. van Goozen, Lodewijk A. Sandkuijl, Richard J. Sinke, B-M Herpertz-Dahlmann, Johannes Hebebrand, Helmut Remschmidt, Hermán van Engeland, R.A.H. Adan	2001	143
7	A3 Domain Is Essential for Interaction of von Willebrand Factor with Collagen Type III Thrombosis and Haemostasis ·H. Lankhof, Maggy van Hoeij, Marion E. Schiphorst, Madelon Bracke, Yaping Wu, Martin J. W. IJsseldijk, Tom Vink, Philip G. de Groot, Jan J. Sixma	1996	128
8	Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63 Molecular Cancer Therapeutics ·Bart E.C.G. de Goeij, Tom Vink, Hendrik ten Napel, Esther C.W. Breij, David Satijn, Richard Wubbolts, David Miao, Paul W.H.I. Parren	2016	111
9	Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3–CH3 Interaction Strength The Journal of Immunology ·Aran F. Labrijn, Theo Rispens, Joyce Meesters, Rebecca Rose, Tamara H. den Bleker, Stefan Loverix, Ewald T.J. van den Bremer, Joost Neijssen, Tom Vink, Ignace Lasters, Rob C. Aalberse, Albert J. R. Heck, Jan G. J. van de Winkel, Janine Schuurman, Paul W.H.I. Parren	2011	107
10	A simple, robust and highly efficient transient expression system for producing antibodies Methods ·Tom Vink, Maroeska Oudshoorn-Dickmann, Marcel Roza, Jelte-Jan Reitsma, Rob N. de Jong	2013	103
11	Mutants of the elongation factor EF‐Tu, a new class of nonsense suppressors. The EMBO Journal ·Erik Vijgenboom, Tom Vink, Barend Kraal, Ludo Van Den Bosch	1985	74
12	N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG Biotechnology Progress ·Patrick H.C. van Berkel, Jolanda Gerritsen, Gerrard J. Perdok, Jesper Valbjørn, Tom Vink, Jan G. J. van de Winkel, Paul W.H.I. Parren	2009	71
13	Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen Blood ·PJ van Genderen, Tom Vink, JJ Michiels, MB van 't Veer, J J Sixma, HH van Vliet	1994	70
14	Platelet Thrombus Formation on Collagen at High Shear Rates Is Mediated by von Willebrand Factor–Glycoprotein Ib Interaction and Inhibited by von Willebrand Factor–Glycoprotein IIb/IIIa Interaction Arteriosclerosis Thrombosis and Vascular Biology ·Yaping Wu, Tom Vink, Marion E. Schiphorst, G. Henrita van Zanten, Martin J. W. IJsseldijk, Philip G. de Groot, Jan J. Sixma	2000	68
15	Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor Blood ·H. Lankhof, YP Wu, Tom Vink, ME Schiphorst, Hans‐Günter Zerwes, PG de Groot, JJ Sixma	1995	64
16	Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG mAbs ·Rebecca Rose, Patrick H.C. van Berkel, Ewald T.J. van den Bremer, Aran F. Labrijn, Tom Vink, Janine Schuurman, Albert J. R. Heck, Paul W.H.I. Parren	2013	56
17	Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence. Proceedings of the National Academy of Sciences ·Jeroen Eikenboom, Tom Vink, E Briët, J J Sixma, P.H. Reitsma	1994	53
18	Leu 697-->Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease Blood ·Lysiane Hilbert, Christine Gaucher, Christophe de Romeuf, MH Horellou, Tom Vink, Claudine Mazurier	1994	49
19	Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C Blood ·SJ Koppelman, M van Hoeij, Tom Vink, H. Lankhof, ME Schiphorst, C Damas, AJ Vlot, Robert A. Wise, BN Bouma, JJ Sixma	1996	44
20	Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition The Journal of Immunology ·Marije B. Overdijk, Sandra Verploegen, Jeroen H. van den Brakel, Jeroen J. Lammerts van Bueren, Tom Vink, Jan G. J. van de Winkel, Paul W.H.I. Parren, Wim K. Bleeker	2011	41

About Tom Vink

Tom Vink is a scholar working on Radiology, Nuclear Medicine and Imaging, Hematology, Molecular Biology, Immunology and Genetics, having authored 34 papers that have together received 3.8k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (17 papers), Platelet Disorders and Treatments (12 papers), Blood groups and transfusion (9 papers), Glycosylation and Glycoproteins Research (5 papers), HER2/EGFR in Cancer Research (4 papers), Heparin-Induced Thrombocytopenia and Thrombosis (3 papers), Viral Infectious Diseases and Gene Expression in Insects (3 papers) and Biochemical Analysis and Sensing Techniques (3 papers). The work is most often cited by research in Hematology (1.1k citations), Radiology, Nuclear Medicine and Imaging (1.3k citations), Genetics (477 citations), Immunology (947 citations) and Oncology (777 citations). Tom Vink has collaborated with scholars based in Netherlands, Germany and United States. Frequent co-authors include Paul W.H.I. Parren, Jan G. J. van de Winkel, Wim K. Bleeker, Jerry W. Slootstra, Janine Schuurman, Thomas Valerius, Matthias Peipp, Tamara H. den Bleker, Rob C. Aalberse and Marc H. De Baets. Their work appears in journals such as Blood, The Journal of Immunology, Thrombosis and Haemostasis, mAbs and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Tom Vink

Impact in

Papers in i

In The Last Decade

Tom Vink

Tom Vink's Hit Papers

Peers

Countries citing papers authored by Tom Vink

Fields of papers citing papers by Tom Vink

All Works

About Tom Vink

Explore authors with similar magnitude of impact

Papers in